[1]李晶,王捷虹.半夏泻心汤加减对幽门螺旋杆菌相关性萎缩性胃炎患者胃泌素、胃蛋白酶的影响[J].西部中医药,2023,36(09):5-9.[doi:10.12174/j.issn.2096-9600.2023.09.02]
　LI Jing,WANG Jiehong.Effects of Modified Banxia Xiexin Tang on Gastrin and Pepsin in Patients with Helicobacter pylori Associated Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2023,36(09):5-9.[doi:10.12174/j.issn.2096-9600.2023.09.02]
点击复制

半夏泻心汤加减对幽门螺旋杆菌相关性萎缩性胃炎患者胃泌素、胃蛋白酶的影响

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年09期
页码:
5-9
栏目:
出版日期:
2023-09-15

文章信息/Info

Title:
Effects of Modified Banxia Xiexin Tang on Gastrin and Pepsin in Patients with Helicobacter pylori Associated Atrophic Gastritis
作者:
李晶, 王捷虹
陕西中医药大学,陕西 咸阳 712000
Author(s):
LI Jing, WANG Jiehong
Shaanxi University of Chinese Medicine, Xianyang 712000, China
关键词:
萎缩性胃炎; 幽门螺旋杆菌; 胃泌素; 胃蛋白酶; 半夏泻心汤加减
Keywords:
atrophic gastritis; Helicobacter pylori; gastrin; pepsin; modified
分类号:
R259
DOI:
10.12174/j.issn.2096-9600.2023.09.02
文献标志码:
A
摘要:
目的探讨半夏泻心汤加减对幽门螺旋杆菌（helicobacter pylori，Hp）相关性萎缩性胃炎患者胃泌素（gastrin，GA）及胃蛋白酶（pepsin，PG）的影响。 方法将82例Hp相关萎缩性胃炎患者分为观察组和对照组各41例。对照组给予常规西医四联方案治疗，观察组给予半夏泻心汤加减治疗。连续治疗2周后观察两组患者临床疗效、中医证候评分、胃泌素17（Gastrin-17，G-17）、胃蛋白酶Ⅰ（pepsin Ⅰ，PG-Ⅰ）、胃蛋白酶Ⅱ（pepsin Ⅱ，PG-Ⅱ）、白细胞介素6（interleukin-6，IL-6）、血清C反应蛋白（C-reaction protein，CRP）、单核细胞趋化蛋白1（monocyte chemoattractant protein 1，MCP-1）及不良反应发生率等。 结果观察组总有效率为90.24%（37/41），高于对照组的73.17%（30/41）（P＜0.05）。治疗后观察组患者脘腹胀痛、恶心呕吐、反酸、嗳气等评分及PG-I、PG-Ⅱ水平与IL-6、CRP、MCP-1水平均低于对照组（P＜0.05），G-17水平高于对照组。不良反应发生率观察组为14.63%（6/41），对照组为9.76%（4/41），两组比较差异无统计学意义（P＞0.05）。 结论半夏泻心汤加减治疗可改善Hp相关性萎缩性胃炎患者中医证候、GA、胃蛋白酶等血清学指标水平，效果优于常规西医四联方案治疗。
Abstract:
ObjectiveTo survey the effects of modified Banxia Xiexin Tang on GA and PG in patients with Hp associated atrophic gastritis. MethodsAll 82 patients with Hp associated atrophic gastritis were divided into the observation group and the control group, with 41 cases in each group. The control group was given conventional quadruple therapy of Western medicine, and the observation group was treated with modified Banxia Xiexin Tang. To observe clinical effects, TCM syndrome integrals, G-17, PG-Ⅰ, PG-Ⅱ, IL-6, CRP and MCP-1, and the incidence of adverse reaction between both groups after two weeks of treatment consecutively. ResultsTotal effective rate of the observation group was 90.24% (37/41), higher than 73.17% (30/41) of the control group (P<0.05). After the treatment, the observation group was lower than the control group in the scores of abdominal distension and pain, nausea and vomiting, sour regurgitation and belching, the levels of PG-Ⅰ, PG-Ⅱ, IL-6, CRP and MCP-1 (P<0.05), higher than the control group in the levels of G-17. The incidence of adverse reaction of the observation group was 14.63% (6/41), higher than 9.76%(4/41) of the control group, and the difference had no statistical meaning (P>0.05). ConclusionModified Banxia Xiexin Tang could improve TCM syndromes, GA and PG in patients with Hp associated atrophic gastritis, and its effects superior to these of conventional quadruple therapy of Western medicine.

相似文献/References:

[1]樊斗霜.枳实消痞丸(汤)合丹参饮加减治疗慢性萎缩性胃炎32例[J].西部中医药,2013,26(02):72.
　FAN Doushuang.Modified ZhiShi XiaoPiWan(Prescription) and DanShenYin in Treating 32 Cases of Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2013,26(09):72.
[2]刘启泉,王志坤△,李博林.达立通联合三联杀菌疗法根除慢性胃炎幽门螺旋杆菌感染的临床观察[J].西部中医药,2014,27(12):91.
[3]殷宏振,麻春杰.麻春杰教授从“瘀”论治慢性萎缩性胃炎和胃癌前病变经验撷菁[J].西部中医药,2026,39(04):9.[doi:10.12174/j.issn.2096-9600.2026.04.03]
　YIN Hongzhen,MA Chunjie.Professor Ma Chunjie?s Experience in Treating Chronic Atrophic Gastritis and Precancerous Lesions of Gastric Cancer from "Stasis"[J].Western Journal of Traditional Chinese Medicine,2026,39(09):9.[doi:10.12174/j.issn.2096-9600.2026.04.03]
[4]王忻,王静,张志明,等.张志明教授辨治慢性萎缩性胃炎经验总结[J].西部中医药,2025,38(09):22.[doi:10.12174/j.issn.2096-9600.2025.09.04]
　WANG Xin,WANG Jing,Director: ZHANG Zhiming,et al.Summary of Professor Zhang Zhiming’s Experience in Treating Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2025,38(09):22.[doi:10.12174/j.issn.2096-9600.2025.09.04]
[5]张慧,姜璐,陈俊生,等.国医大师李佃贵基于“浊毒”理论辨治慢性萎缩性胃炎癌前病变胃黏膜屏障功能障碍[J].西部中医药,2024,37(08):47.[doi:10.12174/j.issn.2096-9600.2024.08.12]
　ZHANG Hui,JIANG Lu,CHEN Junsheng,et al.National Master of TCM Li Diangui′s Experience in Differentiating and Treating Gastric Mucosal Barrier of Precancerous Lesions in Chronic Atrophic Gastritis Based on "Turbidity-toxin" Theory[J].Western Journal of Traditional Chinese Medicine,2024,37(09):47.[doi:10.12174/j.issn.2096-9600.2024.08.12]
[6]李盟,赵迪,杜燕青,等.参佛胃康治疗慢性萎缩性胃炎胃癌前病变作用机制研究[J].西部中医药,2024,37(09):30.[doi:10.12174/j.issn.2096-9600.2024.09.07]
　LI Meng,ZHAO Di,DU Yanqing,et al.Study on the Mechansim of Shenfo Weikang in the Treatment of Precancerous Lesions of Gastric Cancer: Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2024,37(09):30.[doi:10.12174/j.issn.2096-9600.2024.09.07]
[7]于靖文,刘震,王少丽,等.中药联合四联疗法治疗幽门螺旋杆菌相关慢性萎缩性胃炎的系统评价[J].西部中医药,2025,38(02):51.[doi:10.12174/j.issn.2096-9600.2025.02.14]
　YU Jingwen,LIU Zhen,WANG Shaoli,et al.Systematic Evaluation of Chinese Medicine Combined with Quadruple Therapy in the Treatment of Hp-Related Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2025,38(09):51.[doi:10.12174/j.issn.2096-9600.2025.02.14]

备注/Memo

备注/Memo:
李晶（1990—），女，硕士学位。研究方向：脾胃病的基础与临床研究。陕西省特支计划人才项目（陕办发〔2017〕］46号）。
更新日期/Last Update: 2023-09-15